Sinovac Biotech annual debt-to-equity ratio
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sinovac Biotech Debt-to-Equity Ratio Growth & History (SVA)
Sinovac Biotech's debt-to-equity ratio was 0.11 for fiscal 2025.
View full Sinovac Biotech company overviewSinovac Biotech annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.11 | 0.07 | +140.49% |
| 2024 | 2024-12-31 | 0.05 | 0.01 | +31.73% |
| 2023 | 2023-12-31 | 0.04 | 0.03 | +334.15% |
| 2022 | 2022-12-31 | 0.01 | −0.01 | −46.26% |
| 2021 | 2021-12-31 | 0.02 | −0.15 | −90.73% |
| 2020 | 2020-12-31 | 0.17 | 0.12 | +299.74% |
| 2019 | 2019-12-31 | 0.04 | 0.01 | +46.17% |
| 2018 | 2018-12-31 | 0.03 | −0.19 | −86.97% |
| 2017 | 2017-12-31 | 0.22 | −0.13 | −37.94% |
| 2016 | 2016-12-31 | 0.35 | 0.17 | +89.95% |
| 2015 | 2015-12-31 | 0.19 | −0.20 | −52.34% |
| 2014 | 2014-12-31 | 0.39 | 0.01 | +3.39% |
| 2013 | 2013-12-31 | 0.38 | 0.35 | +1229.05% |
| 2012 | 2012-12-31 | 0.03 | — | — |
Sinovac Biotech quarterly debt-to-equity ratio
Q4.12
Q4.13
Q4.14
Q4.15
Q4.16
Q4.17
Q4.18
Q4.19
Q4.20
Q4.21
Q4.22
Q4.23
Q4.24
Q2.25
Q4.25
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | 0.11 | 0.07 | +140.49% |
| Q2 2025 | 2025-06-30 | 0.11 | — | — |
| Q4 2024 | 2024-12-31 | 0.05 | 0.01 | +31.73% |
| Q4 2023 | 2023-12-31 | 0.04 | 0.03 | +334.15% |
| Q4 2022 | 2022-12-31 | 0.01 | −0.01 | −46.26% |
| Q4 2021 | 2021-12-31 | 0.02 | −0.15 | −90.73% |
| Q4 2020 | 2020-12-31 | 0.17 | 0.12 | +299.74% |
| Q4 2019 | 2019-12-31 | 0.04 | 0.01 | +46.17% |
| Q4 2018 | 2018-12-31 | 0.03 | −0.19 | −86.97% |
| Q4 2017 · Dec 31 | 2017-12-31 | 0.22 | −0.13 | −37.94% |
| Q4 2016 | 2016-12-31 | 0.35 | 0.17 | +89.95% |
| Q4 2015 | 2015-12-31 | 0.19 | −0.20 | −52.34% |
| Q4 2014 | 2014-12-31 | 0.39 | 0.01 | +3.39% |
| Q4 2013 | 2013-12-31 | 0.38 | 0.35 | +1229.05% |
| Q4 2012 | 2012-12-31 | 0.03 | — | — |
Sinovac Biotech debt-to-equity ratio trends
Over the last five fiscal years, Sinovac Biotech's debt-to-equity ratio decreased from 0.17 to 0.11, a change of −0.05. The latest reported quarter, Q4 2025, shows 0.11.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sinovac Biotech source filings ↗